{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:58:10Z","timestamp":1786978690360,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":79,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030890735","type":"print"},{"value":"9783030890742","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/164_2021_443","type":"book-chapter","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T14:05:49Z","timestamp":1617890749000},"page":"137-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist"],"prefix":"10.1007","author":[{"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Setola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Kaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jeanne","family":"Kreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Yuan","family":"Liu-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"443_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-1879","volume":"95","author":"T Akiyama","year":"2015","unstructured":"Akiyama T, Carstens MI, Piecha D, Steppan S, Carstens E (2015) Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. Acta Derm Venereol 95:147\u2013150. https:\/\/doi.org\/10.2340\/00015555-1879","journal-title":"Acta Derm Venereol"},{"key":"443_CR2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/acer.13406","volume":"41","author":"RI Anderson","year":"2017","unstructured":"Anderson RI, Becker HC (2017) Role of the dynorphin\/kappa opioid receptor system in the motivational effects of ethanol alcohol. Clin Exp Res 41:1402\u20131418. https:\/\/doi.org\/10.1111\/acer.13406","journal-title":"Clin Exp Res"},{"key":"443_CR3","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","volume":"30","author":"G Bart","year":"2005","unstructured":"Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30:2254\u20132262. https:\/\/doi.org\/10.1038\/sj.npp.1300811","journal-title":"Neuropsychopharmacology"},{"key":"443_CR4","doi-asserted-by":"publisher","unstructured":"Bloodgood DW, Hardaway JA, Stanhope CM, Pati D, Pina MM, Neira S, Desai S, Boyt KM, Palmiter RD, Kash TL (2020) Kappa opioid receptor and dynorphin signaling in the central amygdala regulates alcohol intake. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-020-0690-z","DOI":"10.1038\/s41380-020-0690-z"},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"11614","DOI":"10.1523\/JNEUROSCI.3769-07.2007","volume":"27","author":"MR Bruchas","year":"2007","unstructured":"Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, Chavkin C (2007) Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 27:11614\u201311623","journal-title":"J Neurosci"},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/acschemneuro.0c00407","volume":"11","author":"D Cao","year":"2020","unstructured":"Cao D, Huang P, Chiu YT, Chen C, Wang H, Li M, Zheng Y, Ehlert FJ, Zhang Y, Liu-Chen LY (2020) Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects. ACS Chem Neurosci 11:3036\u20133050. https:\/\/doi.org\/10.1021\/acschemneuro.0c00407","journal-title":"ACS Chem Neurosci"},{"key":"443_CR501","doi-asserted-by":"publisher","unstructured":"Che T, Majumdar S, Zaidi SA, Ondachi P, McCorvy JD, Wang S, Mosier PD, Uprety R, Vardy E, Krumm BE, Han GW, Lee MY, Pardon E, Steyaert J, Huang XP, Strachan RT, Tribo AR, Pasternak GW, Carroll FI, Stevens RC, Cherezov V, Katritch V, Wacker D, Roth BL (2018) Structure of the nanobody-stabilized active state of the kappa opioid receptor cell 172:55\u201367 e15. https:\/\/doi.org\/10.1016\/j.cell.2017.12.011","DOI":"10.1016\/j.cell.2017.12.011"},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1124\/jpet.301.3.993","volume":"301","author":"KP Cosgrove","year":"2002","unstructured":"Cosgrove KP, Carroll ME (2002) Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis. J Pharmacol Exp Ther 301:993\u20131002. https:\/\/doi.org\/10.1124\/jpet.301.3.993","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0165-6147(86)90257-9","volume":"7","author":"A Cowan","year":"1986","unstructured":"Cowan A, Gmerek DE (1986) In-vivo studies on kappa opioid receptors. Trends Pharmacol Sci 7:69\u201372","journal-title":"Trends Pharmacol Sci"},{"key":"443_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1369-1600.2011.00326.x","volume":"18","author":"C D\u2019Addario","year":"2013","unstructured":"D\u2019Addario C, Caputi FF, Rimondini R, Gandolfi O, Del Borrello E, Candeletti S, Romualdi P (2013) Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. Addict Biol 18:425\u2013433. https:\/\/doi.org\/10.1111\/j.1369-1600.2011.00326.x","journal-title":"Addict Biol"},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","volume":"10","author":"AD Dunn","year":"2019","unstructured":"Dunn AD, Reed B, Erazo J, Ben-Ezra A, Kreek MJ (2019) Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses. ACS Chem Neurosci 10:3590\u20133600. https:\/\/doi.org\/10.1021\/acschemneuro.9b00195","journal-title":"ACS Chem Neurosci"},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00213-020-05543-7","volume":"237","author":"A Dunn","year":"2020","unstructured":"Dunn A, Windisch K, Ben-Ezra A, Pikus P, Morochnik M, Erazo J, Reed B, Kreek MJ (2020) Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice. Psychopharmacology 237:2405\u20132418. https:\/\/doi.org\/10.1007\/s00213-020-05543-7","journal-title":"Psychopharmacology"},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jdermsci.2016.09.008","volume":"84","author":"G Elliott","year":"2016","unstructured":"Elliott G, Vanwersch R, Soeberdt M, Metze D, Lotts T, Stander S, Abels C (2016) Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD. J Dermatol Sci 84:351\u2013354. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.09.008","journal-title":"J Dermatol Sci"},{"key":"443_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","volume":"65","author":"T Endoh","year":"1999","unstructured":"Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, Saitoh A, Suzuki T, Narita M, Tseng L, Nagase H (1999) Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci 65:1685\u20131694","journal-title":"Life Sci"},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0014-2999(99)00815-8","volume":"387","author":"T Endoh","year":"2000","unstructured":"Endoh T, Tajima A, Suzuki T, Kamei J, Narita M, Tseng L, Nagase H (2000) Characterization of the antinociceptive effects of TRK-820 in the rat. Eur J Pharmacol 387:133\u2013140","journal-title":"Eur J Pharmacol"},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1254\/jjp.85.282","volume":"85","author":"T Endoh","year":"2001","unstructured":"Endoh T, Tajima A, Izumimoto N, Suzuki T, Saitoh A, Suzuki T, Narita M, Kamei J, Tseng LF, Mizoguchi H, Nagase H (2001) TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys. Jpn J Pharmacol 85:282\u2013290","journal-title":"Jpn J Pharmacol"},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","volume":"231","author":"KB Freeman","year":"2014","unstructured":"Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL (2014) Assessment of the kappa opioid agonist, salvinorin a, as a punisher of drug self-administration in monkeys. Psychopharmacology 231:2751\u20132758. https:\/\/doi.org\/10.1007\/s00213-014-3436-2","journal-title":"Psychopharmacology"},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"eaaz3140","DOI":"10.1126\/scisignal.aaz3140","volume":"13","author":"A Gillis","year":"2020","unstructured":"Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P, Santiago M, Fritzwanker S, Schmiedel F, Katte TA, Reekie T, Grimsey NL, Kassiou M, Kellam B, Krasel C, Halls ML, Connor M, Lane JR, Schulz S, Christie MJ, Canals M (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal 13:eaaz3140. https:\/\/doi.org\/10.1126\/scisignal.aaz3140","journal-title":"Sci Signal"},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1196\/annals.1316.050","volume":"1025","author":"K Hasebe","year":"2004","unstructured":"Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M, Nagase H, Suzuki T (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404\u2013413. https:\/\/doi.org\/10.1196\/annals.1316.050","journal-title":"Ann N Y Acad Sci"},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"107984","DOI":"10.1016\/j.neuropharm.2020.107984","volume":"167","author":"HL Haun","year":"2020","unstructured":"Haun HL, Griffin WC, Lopez MF, Becker HC (2020) Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice. Neuropharmacology 167:107984. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107984","journal-title":"Neuropharmacology"},{"key":"443_CR20","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","volume":"237","author":"SL Huskinson","year":"2020","unstructured":"Huskinson SL, Platt DM, Brasfield M, Follett ME, Prisinzano TE, Blough BE, Freeman KB (2020) Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys. Psychopharmacology 237:2075\u20132087. https:\/\/doi.org\/10.1007\/s00213-020-05519-7","journal-title":"Psychopharmacology"},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejphar.2004.09.010","volume":"502","author":"S Inan","year":"2004","unstructured":"Inan S, Cowan A (2004) Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol 502:233\u2013237","journal-title":"Eur J Pharmacol"},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pbb.2006.07.004","volume":"85","author":"S Inan","year":"2006","unstructured":"Inan S, Cowan A (2006) Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 85:39\u201343","journal-title":"Pharmacol Biochem Behav"},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuroscience.2009.06.016","volume":"163","author":"S Inan","year":"2009","unstructured":"Inan S, Dun NJ, Cowan A (2009a) Nalfurafine prevents 5\u2032-guanidinonaltrindole- and compound 48\/80-induced spinal c-fos expression and attenuates 5\u2032-guanidinonaltrindole-elicited scratching behavior in mice. Neuroscience 163:23\u201333","journal-title":"Neuroscience"},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00210-008-0358-8","volume":"379","author":"S Inan","year":"2009","unstructured":"Inan S, Lee DY, Liu-Chen LY, Cowan A (2009b) Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin a. Naunyn Schmiedeberg's Arch Pharmacol 379:263\u2013270","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"443_CR25","first-page":"451","volume":"217","author":"ET Iwamoto","year":"1981","unstructured":"Iwamoto ET (1981) Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J Pharmacol Exp Ther 217:451\u2013460","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neuron.2014.02.046","volume":"82","author":"AP Kardon","year":"2014","unstructured":"Kardon AP, Polgar E, Hachisuka J, Snyder LM, Cameron D, Savage S, Cai X, Karnup S, Fan CR, Hemenway GM, Bernard CS, Schwartz ES, Nagase H, Schwarzer C, Watanabe M, Furuta T, Kaneko T, Koerber HR, Todd AJ, Ross SE (2014) Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. Neuron 82:573\u2013586. https:\/\/doi.org\/10.1016\/j.neuron.2014.02.046","journal-title":"Neuron"},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/jpet.118.255661","volume":"371","author":"SW Kaski","year":"2019","unstructured":"Kaski SW, White AN, Gross JD, Trexler KR, Wix K, Harland AA, Prisinzano TE, Aube J, Kinsey SG, Kenakin T, Siderovski DP, Setola V (2019) Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine. J Pharmacol Exp Ther 371:487\u2013499. https:\/\/doi.org\/10.1124\/jpet.118.255661","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.biopsych.2013.03.014","volume":"75","author":"JL Kissler","year":"2014","unstructured":"Kissler JL, Sirohi S, Reis DJ, Jansen HT, Quock RM, Smith DG, Walker BM (2014) The one-two punch of alcoholism: role of central amygdala dynorphins\/kappa-opioid receptors. Biol Psychiatry 75:774\u2013782. https:\/\/doi.org\/10.1016\/j.biopsych.2013.03.014","journal-title":"Biol Psychiatry"},{"key":"443_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.108.143925","volume":"328","author":"MC Ko","year":"2009","unstructured":"Ko MC, Husbands SM (2009) Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193\u2013200. https:\/\/doi.org\/10.1124\/jpet.108.143925","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","volume":"73","author":"GF Koob","year":"2021","unstructured":"Koob GF (2021) Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development. Pharmacol Rev 73:163\u2013201. https:\/\/doi.org\/10.1124\/pharmrev.120.000083","journal-title":"Pharmacol Rev"},{"key":"443_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/IJNRD.S145720","volume":"11","author":"H Kozono","year":"2018","unstructured":"Kozono H, Yoshitani H, Nakano R (2018) Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch((R)) capsules 2.5 mug) in 3,762 hemodialysis patients with intractable pruritus. Int J Nephrol Renovasc Dis 11:9\u201324. https:\/\/doi.org\/10.2147\/IJNRD.S145720","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"443_CR32","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H (2010) Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25:1251\u20131257. https:\/\/doi.org\/10.1093\/ndt\/gfp588","journal-title":"Nephrol Dial Transplant"},{"key":"443_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000341268","volume":"36","author":"H Kumagai","year":"2012","unstructured":"Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, Kurihara M, Yanagita T, Suzuki H (2012) Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 36:175\u2013183. https:\/\/doi.org\/10.1159\/000341268","journal-title":"Am J Nephrol"},{"key":"443_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.alcohol.2011.05.001","volume":"45","author":"MP Lam","year":"2011","unstructured":"Lam MP, Gianoulakis C (2011) Effects of corticotropin-releasing hormone receptor antagonists on the ethanol-induced increase of dynorphin A1-8 release in the rat central amygdala. Alcohol 45:621\u2013630. https:\/\/doi.org\/10.1016\/j.alcohol.2011.05.001","journal-title":"Alcohol"},{"key":"443_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00213-017-4758-7","volume":"235","author":"ML Lazenka","year":"2018","unstructured":"Lazenka ML, Moerke MJ, Townsend EA, Freeman KB, Carroll FI, Negus SS (2018) Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain\/itch-stimulated and pain\/itch-depressed behaviors in male rats. Psychopharmacology 235:203\u2013213. https:\/\/doi.org\/10.1007\/s00213-017-4758-7","journal-title":"Psychopharmacology"},{"key":"443_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0166-4328(00)00368-5","volume":"120","author":"S Lindholm","year":"2001","unstructured":"Lindholm S, Werme M, Bren\u00e9 S, Franck J (2001) The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res 120:137\u2013146. https:\/\/doi.org\/10.1016\/s0166-4328(00)00368-5","journal-title":"Behav Brain Res"},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"eaao4927","DOI":"10.1126\/science.aao4927","volume":"360","author":"JJ Liu","year":"2018","unstructured":"Liu JJ, Sharma K, Zangrandi L, Chen C, Humphrey SJ, Chiu YT, Spetea M, Liu-Chen LY, Schwarzer C, Mann M (2018) In vivo brain GPCR signaling elucidated by phosphoproteomics. Science 360:eaao4927. https:\/\/doi.org\/10.1126\/science.aao4927","journal-title":"Science"},{"key":"443_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","volume":"44","author":"JJ Liu","year":"2019","unstructured":"Liu JJ, Chiu YT, DiMattio KM, Chen C, Huang P, Gentile TA, Muschamp JW, Cowan A, Mann M, Liu-Chen LY (2019) Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion. Neuropsychopharmacology 44:939\u2013949. https:\/\/doi.org\/10.1038\/s41386-018-0155-0","journal-title":"Neuropsychopharmacology"},{"key":"443_CR39","first-page":"812","volume":"286","author":"NK Mello","year":"1998","unstructured":"Mello NK, Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812\u2013824","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR40","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","volume":"94","author":"AS Morani","year":"2009","unstructured":"Morani AS, Kivell B, Prisinzano TE, Schenk S (2009) Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin a on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 94:244\u2013249. https:\/\/doi.org\/10.1016\/j.pbb.2009.09.002","journal-title":"Pharmacol Biochem Behav"},{"key":"443_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","volume":"161","author":"T Mori","year":"2002","unstructured":"Mori T, Nomura M, Nagase H, Narita M, Suzuki T (2002) Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology (Berlin) 161:17\u201322","journal-title":"Psychopharmacology (Berlin)"},{"key":"443_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/BF00432213","volume":"86","author":"RF Mucha","year":"1985","unstructured":"Mucha RF, Herz A (1985) Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274\u2013280","journal-title":"Psychopharmacology"},{"key":"443_CR502","doi-asserted-by":"crossref","unstructured":"Nagase H, Fujii H (2013) Essential structure of the kappa opioid receptor agonist nalfurafine for binding to the kappa receptor. Curr Pharm Des 19:7400\u20137414","DOI":"10.2174\/138161281942140105165011"},{"key":"443_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1248\/cpb.46.366","volume":"46","author":"H Nagase","year":"1998","unstructured":"Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, Tajima C, Endo T (1998) Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull (Tokyo) 46:366\u2013369","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"443_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1358\/dot.2009.45.5.1362067","volume":"45","author":"K Nakao","year":"2009","unstructured":"Nakao K, Mochizuki H (2009a) Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today (Barc) 45:323\u2013329. https:\/\/doi.org\/10.1358\/dot.2009.45.5.1362067","journal-title":"Drugs Today (Barc)"},{"key":"443_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1358\/dot.2009.45.5.1377595","volume":"45","author":"K Nakao","year":"2009","unstructured":"Nakao K, Mochizuki H (2009b) Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today (Barc) 45:323\u2013329","journal-title":"Drugs Today (Barc)"},{"key":"443_CR46","first-page":"75","volume":"28","author":"K Nakao","year":"2008","unstructured":"Nakao K, Ikeda K, Kurokawa T, Togashi Y, Umeuchi H, Honda T, Okano K, Mochizuki H (2008) Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis. Nihon Shinkei Seishin Yakurigaku Zasshi 28:75\u201383","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"443_CR47","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/a0013088","volume":"16","author":"SS Negus","year":"2008","unstructured":"Negus SS, Schrode K, Stevenson GW (2008) Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386\u2013399. https:\/\/doi.org\/10.1037\/a0013088","journal-title":"Exp Clin Psychopharmacol"},{"key":"443_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00002826-199619050-00009","volume":"19","author":"AC Pande","year":"1996","unstructured":"Pande AC, Pyke RE, Greiner M, Wideman GL, Benjamin R, Pierce MW (1996) Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin Neuropharmacol 19:451\u2013456","journal-title":"Clin Neuropharmacol"},{"key":"443_CR49","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774\u2013776. https:\/\/doi.org\/10.1126\/science.3016896","journal-title":"Science"},{"key":"443_CR50","doi-asserted-by":"publisher","unstructured":"Rose JH, Karkhanis AN, Chen R, Gioia D, Lopez MF, Becker HC, McCool BA, Jones SR (2016) Supersensitive kappa opioid receptors promotes ethanol withdrawal-related behaviors and reduce dopamine signaling in the nucleus accumbens. Int J Neuropsychopharmacol 19. https:\/\/doi.org\/10.1093\/ijnp\/pyv127","DOI":"10.1093\/ijnp\/pyv127"},{"key":"443_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/AAP.0000000000000326","volume":"41","author":"M Sakakihara","year":"2016","unstructured":"Sakakihara M, Imamachi N, Saito Y (2016) Effects of intrathecal kappa-opioid receptor agonist on morphine-induced itch and antinociception in mice. Reg Anesth Pain Med 41:69\u201374. https:\/\/doi.org\/10.1097\/AAP.0000000000000326","journal-title":"Reg Anesth Pain Med"},{"key":"443_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","volume":"32","author":"SS Schattauer","year":"2017","unstructured":"Schattauer SS, Kuhar JR, Song A, Chavkin C (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59\u201365. https:\/\/doi.org\/10.1016\/j.cellsig.2017.01.016","journal-title":"Cell Signal"},{"key":"443_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0014-2999(99)00369-6","volume":"376","author":"T Seki","year":"1999","unstructured":"Seki T, Awamura S, Kimura C, Ide S, Sakano K, Minami M, Nagase H, Satoh M (1999) Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur J Pharmacol 376:159\u2013167","journal-title":"Eur J Pharmacol"},{"key":"443_CR54","first-page":"563","volume":"75","author":"TS Shippenberg","year":"1986","unstructured":"Shippenberg TS, Herz A (1986) Differential effects of mu and kappa opioid systems on motivational processes NIDA. Res Monogr 75:563\u2013566","journal-title":"Res Monogr"},{"key":"443_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bph.12692","volume":"172","author":"B Simonson","year":"2015","unstructured":"Simonson B, Morani AS, Ewald AW, Walker L, Kumar N, Simpson D, Miller JH, Prisinzano TE, Kivell BM (2015) Pharmacology and anti-addiction effects of the novel \u03ba opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin a. Br J Pharmacol 172:515\u2013531. https:\/\/doi.org\/10.1111\/bph.12692","journal-title":"Br J Pharmacol"},{"key":"443_CR56","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.neuron.2018.08.044","volume":"99","author":"LM Snyder","year":"2018","unstructured":"Snyder LM, Chiang MC, Loeza-Alcocer E, Omori Y, Hachisuka J, Sheahan TD, Gale JR, Adelman PC, Sypek EI, Fulton SA, Friedman RL, Wright MC, Duque MG, Lee YS, Hu Z, Huang H, Cai X, Meerschaert KA, Nagarajan V, Hirai T, Scherrer G, Kaplan DH, Porreca F, Davis BM, Gold MS, Koerber HR, Ross SE (2018) Kappa opioid receptor distribution and function in primary afferents. Neuron 99:1274\u20131288.e1276. https:\/\/doi.org\/10.1016\/j.neuron.2018.08.044","journal-title":"Neuron"},{"key":"443_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1124\/jpet.103.059816","volume":"309","author":"I Takasaki","year":"2004","unstructured":"Takasaki I, Suzuki T, Sasaki A, Nakao K, Hirakata M, Okano K, Tanaka T, Nagase H, Shiraki K, Nojima H, Kuraishi Y (2004) Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (\u2212)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans \u22123-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice. J Pharmacol Exp Ther 309:36\u201341. https:\/\/doi.org\/10.1124\/jpet.103.059816","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","volume":"435","author":"Y Togashi","year":"2002","unstructured":"Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, Kawamura K, Endoh T, Utsumi J, Kamei J, Tanaka T, Nagase H (2002) Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435:259\u2013264","journal-title":"Eur J Pharmacol"},{"key":"443_CR59","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","volume":"234","author":"EA Townsend","year":"2017","unstructured":"Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology 234:2597\u20132605. https:\/\/doi.org\/10.1007\/s00213-017-4652-3","journal-title":"Psychopharmacology"},{"key":"443_CR60","doi-asserted-by":"publisher","first-page":"L353","DOI":"10.1016\/S0024-3205(00)00582-8","volume":"66","author":"M Tsuji","year":"2000","unstructured":"Tsuji M, Takeda H, Matsumiya T, Nagase H, Yamazaki M, Narita M, Suzuki T (2000a) A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci 66:L353\u2013L358","journal-title":"Life Sci"},{"key":"443_CR61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0014-2999(00)00139-4","volume":"394","author":"M Tsuji","year":"2000","unstructured":"Tsuji M, Yamazaki M, Takeda H, Matsumiya T, Nagase H, Tseng LF, Narita M, Suzuki T (2000b) The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur J Pharmacol 394:91\u201395","journal-title":"Eur J Pharmacol"},{"key":"443_CR62","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/S0024-3205(01)00957-2","volume":"68","author":"M Tsuji","year":"2001","unstructured":"Tsuji M, Takeda H, Matsumiya T, Nagase H, Narita M, Suzuki T (2001) The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci 68:1717\u20131725","journal-title":"Life Sci"},{"key":"443_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejphar.2003.08.007","volume":"477","author":"H Umeuchi","year":"2003","unstructured":"Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H (2003) Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 477:29\u201335","journal-title":"Eur J Pharmacol"},{"key":"443_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2005.06.019","volume":"518","author":"H Umeuchi","year":"2005","unstructured":"Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H (2005) Spontaneous scratching behavior in MRL\/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride. Eur J Pharmacol 518:133\u2013139. https:\/\/doi.org\/10.1016\/j.ejphar.2005.06.019","journal-title":"Eur J Pharmacol"},{"key":"443_CR65","first-page":"7","volume":"224","author":"PF von Voigtlander","year":"1983","unstructured":"von Voigtlander PF, Lahti RA, Ludens JH (1983) U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 224:7\u201312","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR66","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","volume":"9","author":"ML Wadenberg","year":"2003","unstructured":"Wadenberg ML (2003) A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev 9:187\u2013198","journal-title":"CNS Drug Rev"},{"key":"443_CR67","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1016\/j.lfs.2004.05.033","volume":"75","author":"Y Wakasa","year":"2004","unstructured":"Wakasa Y, Fujiwara A, Umeuchi H, Endoh T, Okano K, Tanaka T, Nagase H (2004) Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 75:2947\u20132957. https:\/\/doi.org\/10.1016\/j.lfs.2004.05.033","journal-title":"Life Sci"},{"key":"443_CR68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s002130100788","volume":"157","author":"SL Walsh","year":"2001","unstructured":"Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151\u2013162. https:\/\/doi.org\/10.1007\/s002130100788","journal-title":"Psychopharmacology"},{"key":"443_CR69","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1124\/jpet.104.073668","volume":"312","author":"Y Wang","year":"2005","unstructured":"Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen L-Y (2005) Comparison of pharmacological activities of three distinct k ligands (Salvinorin a, TRK-820 and 3FLB) on k opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220\u2013230","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","volume":"352","author":"KL White","year":"2015","unstructured":"White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL (2015) The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther 352:98\u2013109. https:\/\/doi.org\/10.1124\/jpet.114.216820","journal-title":"J Pharmacol Exp Ther"},{"key":"443_CR71","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","volume":"237","author":"CA Zamarripa","year":"2020","unstructured":"Zamarripa CA, Naylor JE, Huskinson SL, Townsend EA, Prisinzano TE, Freeman KB (2020a) Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology 237:1471\u20131480. https:\/\/doi.org\/10.1007\/s00213-020-05473-4","journal-title":"Psychopharmacology"},{"key":"443_CR72","doi-asserted-by":"publisher","unstructured":"Zamarripa CA, Patel TR, Williams BC, Pareek T, Schrock HM, Prisinzano TE, Freeman KB (2020b) The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats. Behav Pharmacol. https:\/\/doi.org\/10.1097\/FBP.0000000000000581","DOI":"10.1097\/FBP.0000000000000581"},{"key":"443_CR73","doi-asserted-by":"publisher","first-page":"108244","DOI":"10.1016\/j.neuropharm.2020.108244","volume":"176","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Kreek MJ (2020) Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice. Neuropharmacology 176:108244. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108244","journal-title":"Neuropharmacology"},{"key":"443_CR74","doi-asserted-by":"publisher","first-page":"146410","DOI":"10.1016\/j.brainres.2019.146410","volume":"1724","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Kreek MJ (2019a) Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. Brain Res 1724:146410. https:\/\/doi.org\/10.1016\/j.brainres.2019.146410","journal-title":"Brain Res"},{"key":"443_CR75","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/acer.14033","volume":"43","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Kreek MJ (2019b) Combination of clinically utilized kappa-opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice. Alcohol Clin Exp Res 43:1077\u20131090. https:\/\/doi.org\/10.1111\/acer.14033","journal-title":"Alcohol Clin Exp Res"},{"key":"443_CR76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.neulet.2013.08.071","volume":"554","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Colombo G, Gessa GL, Kreek MJ (2013) Effects of voluntary alcohol drinking on corticotropin-releasing factor and preprodynorphin mRNA levels in the central amygdala of Sardinian alcohol-preferring rats. Neurosci Lett 554:110\u2013114. https:\/\/doi.org\/10.1016\/j.neulet.2013.08.071","journal-title":"Neurosci Lett"},{"key":"443_CR77","doi-asserted-by":"publisher","first-page":"172954","DOI":"10.1016\/j.pbb.2020.172954","volume":"195","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Liang Y, Kreek MJ (2020) mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice. Pharmacol Biochem Behav 195:172954. https:\/\/doi.org\/10.1016\/j.pbb.2020.172954","journal-title":"Pharmacol Biochem Behav"}],"container-title":["Handbook of Experimental Pharmacology","The Kappa Opioid Receptor"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2021_443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T21:10:14Z","timestamp":1637788214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2021_443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030890735","9783030890742"],"references-count":79,"URL":"https:\/\/doi.org\/10.1007\/164_2021_443","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"9 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}